A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles

IF 30.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Lancet Gastroenterology & Hepatology Pub Date : 2025-05-20 DOI:10.1016/s2468-1253(25)00068-8

Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Behzad Hajarizadeh, Victoria Turnier, Jeffrey V Lazarus, Jason Grebely, Gregory J Dore, Imam Waked, John W Ward

{"title":"A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles","authors":"Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Behzad Hajarizadeh, Victoria Turnier, Jeffrey V Lazarus, Jason Grebely, Gregory J Dore, Imam Waked, John W Ward","doi":"10.1016/s2468-1253(25)00068-8","DOIUrl":null,"url":null,"abstract":"The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development for the elimination of viral hepatitis. To date, profiles from 33 countries and territories have been developed. These profiles reveal that 30 (91%) countries and territories have hepatitis C national action plans, 11 (33%) have systems to monitor hepatitis C-related mortality, 16 (48%) have systems to monitor hepatitis C incidence, and 18 (55%) have systems to track the number of people tested and treated. Some countries and territories continue to uphold barriers to hepatitis C treatment, with 12 (36%) still having partial or full restrictions on prescribing authority for non-specialists. Ten (30%) countries and territories have met the WHO 2025 diagnosis coverage target of 60%, five (15%) have met the treatment target of 50%, and seven (21%) have met the needle and syringe exchange target. Although there are examples of countries and territories across the income spectrum meeting these targets, policy development in low-income and middle-income countries and territories generally lags behind that in high-income countries and territories.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"309 1","pages":""},"PeriodicalIF":30.9000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00068-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development for the elimination of viral hepatitis. To date, profiles from 33 countries and territories have been developed. These profiles reveal that 30 (91%) countries and territories have hepatitis C national action plans, 11 (33%) have systems to monitor hepatitis C-related mortality, 16 (48%) have systems to monitor hepatitis C incidence, and 18 (55%) have systems to track the number of people tested and treated. Some countries and territories continue to uphold barriers to hepatitis C treatment, with 12 (36%) still having partial or full restrictions on prescribing authority for non-specialists. Ten (30%) countries and territories have met the WHO 2025 diagnosis coverage target of 60%, five (15%) have met the treatment target of 50%, and seven (21%) have met the needle and syringe exchange target. Although there are examples of countries and territories across the income spectrum meeting these targets, policy development in low-income and middle-income countries and territories generally lags behind that in high-income countries and territories.

查看原文本刊更多论文

关于消除丙型肝炎的国家政策、规划和进展的2024年全球报告：来自33个消除肝炎概况的发现

全球消除肝炎联盟的国家消除肝炎概况评估消除病毒性肝炎的国家数据、政策和规划制定状况。迄今为止，已经编制了33个国家和领土的概况。这些概况显示，30个（91%）国家和领土制定了丙型肝炎国家行动计划，11个（33%）拥有监测丙型肝炎相关死亡率的系统，16个（48%）拥有监测丙型肝炎发病率的系统，18个（55%）拥有跟踪检测和治疗人数的系统。一些国家和地区继续对丙型肝炎治疗设置障碍，12个国家（36%）仍然对非专科医生的处方权实行部分或全部限制。10个（30%）国家和领土实现了世卫组织2025年60%的诊断覆盖率目标，5个（15%）国家和领土实现了50%的治疗目标，7个（21%）国家和领土实现了针头和注射器交换目标。虽然各收入阶层的国家和领土都有实现这些目标的例子，但低收入和中等收入国家和领土的政策制定通常落后于高收入国家和领土。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.